Test the Waters
Corvidane

Corvidane

Developing a novel, safe drug to prevent heart attacks, strokes, and liver transplants from NASH

View on Wefunder
Security Type
SAFE
Industry
Medical
Min Investment
$100
Location
New York, NY
Offering Date
October 18, 2021
Expected Close Date
January 16, 2022

Use of Proceeds

  • Operations 
  • Legal, accounting, market research
  • Manufacturing/CMC
  • Toxicology studies
  • Personnel 

Key Deal Facts

CEO designed trials for Vascepa®, which reduces heart attack and stroke risk for high triglycerides.
Awarded $700k from Dutch government to perform more studies on our drug Corvida™'s potential.
Results of Corvida™'s affect on genes associated with atherosclerosis due in 2022.
Funds raised will lead to PreIND meetings with the FDA to ensure acceptability of human trials.
Corvida™'s components are designated GRAS (Generally Regarded as Safe) by the FDA.
Corvida™ is protected by patents in the US and Japan and are owned by the company.
This is an opportunity for you to impact global health and potentially realize significant financial gains.

Security Description

A SAFE is an agreement between you—the investor—and the company in which the company promises to give you a future equity stake based on the amount you invested. It also involves some kind of a triggering event that must take place in order for you to get your future equity stake. Be careful as you may only get equity if a particular event is triggered.

Research Reports

No reports have been submitted

Become a Reporter

0 Comments